Which biotechs are analysts predicting as the next obesity buyout targets?

Analysts have identified Viking Therapeutics and Structure Therapeutics as leading potential buyout targets in the obesity drug space. Viking’s dual GLP‑1/GIP agonist VK2735 and Structure’s oral candidate aleniglipron both show strong weight‑loss efficacy, drawing attention from major pharmas seeking next‑generation assets.